June 13, 2025

JAK Inhibitors Show No Increased Cancer Risk

New real-world data show no significant rise in overall cancer incidence with JAK inhibitors for rheumatoid arthritis patients, though skin cancer monitoring remains important.

Conexiant

June 12, 2025

Medical Oddities: 6 Foot Moves Possibly Worth Prescribing

Strong feet, smarter carbs, test kits, and tea—this roundup’s got range.

Conexiant

June 12, 2025

Vegetarian Diet Linked to Lower Cancer Incidence

A large North American cohort study found that vegetarian diets were associated with lower risks of several site-specific cancers, including colorectal, stomach, breast, prostate, and lymphoproliferative cancers.

Conexiant

June 11, 2025

8-Week Oral Therapy Approved for Acute HCV

The FDA has approved Mavyret for the treatment of acute hepatitis C, offering physicians a pangenotypic, 8-week oral regimen for early intervention.

Conexiant

June 10, 2025

Improving the Alliance Between Oncologists and Primary Care Providers: A Call for Collaborative Action

Experts and patients alike would agree that navigating the current fragmented U.S. health-care system is not an easy task. One component of that disconnection may center on the relationship between on...

The ASCO Post

June 10, 2025

FDA Pledges Week-Long Drug Reviews

New leadership outlines accelerated approval processes, AI integration, and food additive restrictions to address the chronic disease epidemic

Conexiant

June 09, 2025

Sleep Signals May Shape Survival Odds

A new study found that a shorter time gap between melatonin production and sleep midpoints may be linked to longer survival among women with advanced breast cancer.

Conexiant

June 09, 2025

Appendix Tumors Climb for Millennials, Gen Z

Younger generations—particularly individuals born after 1980—face higher rates of appendiceal cancer, with incidence increasing more than fourfold in recent decades, according to a new study.

Conexiant

June 06, 2025

Lower-Dose Treatment Effective in Anal Cancer Trial, Study

In a recent clinical trial, researchers found that a reduced-dose chemoradiotherapy regimen for early-stage anal cancer may be comparable to standard treatment in achieving short-term tumor response, while causing fewer serious side effects.

Conexiant